Division of di Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S7-14. Epub 2011 Jul 26.
Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations and, to this end, a systematic literature review was carried out and the evidence derived from it was discussed and summarised as expert opinions. Levels of evidence, strength of recommendations and levels of agreement were reported. The recommendations reported are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.
鉴于新型生物制剂可用于治疗类风湿关节炎（RA），为了帮助风湿病学家开具这些药物，各个国家的科学学会制定了具体的建议。意大利风湿病学会（Società Italiana di Reumatologia，SIR）决定更新其建议，为此，进行了系统的文献回顾，并对从中得出的证据进行了讨论和总结为专家意见。报告了证据水平、建议强度和一致性水平。报告的建议旨在帮助处方风湿病学家在日常实践中优化 RA 患者使用生物制剂；这些建议不应被视为监管规则。
